Company profile: Bachem
1.1 - Company Overview
Company description
- Provider of full-service biochemicals to the pharma and biotech industry; an independent, technology-based company specializing in process development and GMP manufacturing of peptide and oligonucleotide APIs, complex organic molecules, and innovative research biochemicals. Offers research-grade and GMP peptides, oligonucleotide NCE development, commercial APIs and generics, catalog peptides, custom peptide synthesis, amino acid derivatives, and products for diagnostics and cosmetics.
Products and services
- Commercial API: Produces GMP-grade new chemical entities (NCEs) and high-demand generic products as APIs for the pharma and biotech industry
- Oligonucleotide NCEs: Develops and fabricates oligonucleotide-based APIs with process development, GMP manufacturing, and regulatory guidance to progress new chemical entities
- Peptide NCEs: Engineers production of research-grade and GMP-grade peptides, including complex peptidomimetics and synthetic proteins for pharmaceutical research and development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Bachem
Halo Pharma
HQ: United States
Website
- Description: Provider of contract dosage form development, manufacturing, and testing services to the pharmaceutical, biotechnology, and generic industries. Services include product development to commercial manufacturing; formulation and analytical development; clinical manufacturing and packaging; solid dosage production (tablets, capsules, powders, granules, micro-tablets, multi-particulates), and clinical supplies for liquids, suspensions, and powder-in-bottle.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Halo Pharma company profile →
Phaxiam Therapeutics
HQ: France
Website
- Description: Provider of bacteriophage-based therapies to combat antimicrobial-resistant bacterial infections, offering phage treatments, GMP individualized phage therapies (IPT), standardized phage therapies medicinal products (PTMP), a phage portfolio targeting Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa, an in vitro Phagogram test for phage susceptibility, and PhagoDAIR clinical trial.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phaxiam Therapeutics company profile →
Cardinal Group
HQ: United States
Website
- Description: Provider of project management and building practitioner services and solutions focused on delivering pharmaceutical and biotechnology construction projects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cardinal Group company profile →
Tobin Scientific
HQ: United States
Website
- Description: Provider of life science lab relocation, biorepository, and portable cold storage, offering cold chain transport and storage; ULT transport via ultra-low temperature generator trailers across North America; mobile cold rooms with robust temperature control and monitoring; and cGMP-compliant ambient warehousing with advanced temperature and humidity control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tobin Scientific company profile →
Liverpool ChiroChem
HQ: United Kingdom
Website
- Description: Provider of chiral small molecules for biotech/pharma R&D, offering specialist building blocks, fragments and screening compounds to enable small molecule drug discovery, plus ultra-large (1.4B), covalent (800k) and kinase-focused (4.5M) virtual libraries, DEL synthons, heterobifunctional linkers, and a parallel synthesis lab producing up to 5,000 compounds per month.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Liverpool ChiroChem company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Bachem
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Bachem
2.2 - Growth funds investing in similar companies to Bachem
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Bachem
4.2 - Public trading comparable groups for Bachem
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →